DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852

Our STN: BL 103950/5039

APR 23 2004

Amgen, Incorporated
Attention: Douglas Hunt
Director, Regulatory Affairs
One Amgen Drive
Thousand Oaks, CA 91320-1799

Dear Mr. Hunt:

Your request to supplement your biologics license application for Anakinra to update the Patient Package Insert and the Adverse Events section of the package insert (PI) based upon three year safety data, and, to revise the Clinical Pharmacology: Pharmacokinetics, and the Dosage and Administration sections of the PI have been approved.

This fulfills postmarketing commitment number 2 identified in the November 14, 2001 approval letter for your submission BL 103950/0as described below:

- To submit data from an ongoing study to evaluate the ability of Anakinra to slow radiographic disease progression. The protocol for study 990145 entitled "A Multicenter, Blinded, Randomized, Placebo-Controlled Trial to Study the Ability of IL-1ra (Anakinra) to Retard Joint Destruction, and Evaluate the Long-Term Safety of IL-1ra in Subjects with Rheumatoid Arthritis" was submitted to IND 3611 on August 25, 1999. Patient accrual was completed on January 31, 2001, the study will be completed by February 28, 2002, and the final study report will be submitted by July 31, 2002.

Pursuant to 21 CFR 201.57(f)(2), patient labeling must be reprinted at the end of the package insert. We request that the text of information distributed to patients be printed in a minimum of 10 point font.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

The regulatory responsibility for review and continuing oversight for this product transferred from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research effective June 30, 2003. For further information about the transfer, please see http://www.fda.gov/cder/biologics/default.htm. Until further notice, however, all correspondence, except as provided elsewhere in this letter, should continue to be addressed to:

CBER Document Control Center
Attn: Office of Therapeutics Research and Review
Suite 200N (HFM-99)
1401 Rockville Pike
Rockville, Maryland 20852-1448

This information will be included in your biologics license application file.

Sincerely,

(b)(6)

Marc Walton, M.D., Ph.D.
Director
Division of Therapeutic Biological Internal Medicine Products
Office of Drug Evaluation VI
Office of New Drugs
Center for Drug Evaluation and Research

CONCURRENCE PAGE

Letter Type: LETTER: Approval (AP)
Summary Text: Clinical Supplmt. – Labeling Only
REVIEW COMPLETION REQUIRED BY: RIS

SS Data Check:
- **Place copy of Approval Ltr. with original signature concurrence page in Archival package behind the "Approval Materials" Tab after LAR (Licensing Action Recommendation).**

RIS Data Check:
- **Verify short summary – Ltr. & Submission screen should match.**
- **Check Letter for PMCs (if PMCs – add "PMCs – Approved With" special characteristic code.)**
- **Perform Review Completion Process**
- **Milestone: Confirm Approved Status**

cc: M. Walton HFM-576
E. Unger HFM-576
DRMP BLA file, HFM-585
K. Weiss HFM-500
QAS, HFM-4
RIMS, HFM-110
Carole Broadnax, (with final draft PI)
E. Rivera-Martinez, IPCB, HFD-322

History: michaloski\4.20.04

File Name: S:\michaloski\letters\103950.5039ap

(b)(6)